GLP-1 Drugs (U.S.): 2023 Pulse Survey
A new survey report from the International Foundation reveals U.S. employer coverage and considerations surrounding glucagon-like peptide-1 (GLP-1) drugs. Among survey respondents, 76% provide GLP-1 drug coverage for diabetes, 27% provide coverage for weight loss, and 13% are considering covering for weight loss.
Related Word on Benefits Blog Posts:
Top Ten Factors Regarding GLP-1 Coverage for Obesity Care* (n=205)
*Respondents were asked to select all that apply.
Coverage of GLP-1 Drugs* (n=205)
*Respondents were asked to select up to two responses.
Cost-Control Mechanisms in Place for GLP-1 Drugs for Weight Loss* (n=56)
*Respondents were asked to select all that apply.
Representation of GLP-1 Drugs for Weight Loss in Total Annual Claims for 2023 (n=56)
Average
6.9%
There's more! View a full listing of International Foundation benchmarking and pulse survey reports.
Survey reports are just one of the many helpful products and services included with an International Foundation membership.